We give you a written timeline estimate for your case before you commit.Ask about treatment
Acromegaly: US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Acromegaly: the short answer
The US FDA has approved two medicines covered on this page for acromegaly, each for a specific group of patients: Somavert and Mycapssa. On 17 October 2026, one of them was on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Somavert and Mycapssa.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is acromegaly?
Acromegaly is a disorder in which the body makes too much growth hormone. Growth hormone is made mainly in the pituitary gland at the base of the brain. In adults, too much of it makes bones, cartilage, organs and other tissues grow larger, so the nose, ears, hands and feet can become enlarged or swollen. In children, the same problem causes gigantism instead.[1]
The cause is usually a noncancerous (benign) tumor of the pituitary gland. Because the changes come on slowly, other health problems can develop before diagnosis, such as type 2 diabetes, high blood pressure, heart disease, sleep apnea, arthritis and carpal tunnel syndrome. People with acromegaly also have a higher risk of colon polyps.[1, 2]
Acromegaly is rare. Scientists estimate that about 3 to 14 of every 100,000 people have been diagnosed with it. Treatment usually starts with surgery to remove the tumor, with medicines and radiation therapy used when surgery is not enough or not possible.[1]
Acromegaly in the Gulf
Doctors in the Gulf have published their own experience with acromegaly, including a 2020 study of clinical presentation, treatment and outcome in the United Arab Emirates, a 2024 study of thyroid disorders in Saudi patients with acromegaly, and a 2025 study of surgical outcomes in Qatar.[3, 4, 5]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 1 of 2 was listed in Saudi Arabia and 1 of 2 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[6, 7]
US FDA-approved medicines for acromegaly
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Somavert (pegvisomant)
US FDA-approved for adults with acromegaly who have not responded well enough to surgery or radiation therapy, or for whom these treatments are not suitable. It blocks the effect of growth hormone and is given as an injection under the skin.[8]
Current US label version: 18 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7] - Mycapssa (octreotide)
US FDA-approved for long-term maintenance treatment in adults with acromegaly who have already responded to and tolerated octreotide or lanreotide injections. It is a capsule taken by mouth.[9]
Current US label version: 24 July 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found under this brand; products with the same active ingredient are listed (for example Ocran, Octreotide, Sandostatin). Abu Dhabi (DoH drug code list): not found under this brand; products with the same active ingredient are listed (for example Octreotide, Sandostatin). Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[6, 7]
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for acromegaly
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for acromegaly?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Somavert and Mycapssa. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Somavert available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Somavert?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Is acromegaly treated with medicine or surgery?
Surgery to remove the pituitary tumor is usually the first treatment. Medicines and radiation therapy are used when surgery does not fully control growth hormone or is not an option. The US labels for Somavert and Mycapssa describe use after or alongside these steps.
Sources for the condition-specific answers: [1, 8, 9]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Acromegaly
- MedlinePlus (US National Library of Medicine): Acromegaly
- Al Dahmani K, et al. Clinical Presentation, Treatment, and Outcome of Acromegaly in the United Arab Emirates. Oman Med J. 2020 (PubMed 32995046)
- Alsuraikh MA, et al. Thyroid Disorders in Saudi Patients With Acromegaly: A Tertiary Care Center Experience. Cureus. 2024 (PubMed 38455769)
- Ahmed A, et al. Surgical Outcomes and Complications of Patients With Acromegaly in Qatar. Cureus. 2025 (PubMed 41111823)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: SOMAVERT (pegvisomant) US prescribing information, label version 18 December 2025
- DailyMed: MYCAPSSA (octreotide) US prescribing information, label version 24 July 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Cushing's syndrome
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.